
Sana Sukhun and Aleix Prat
Dec 13, 2024, 17:04
Sana Sukhun: SHR-A1811 demonstrating non-inferiority to the standard quadruple therapy in early Breast Cancer
Sana Sukhun, Co-Chair of RSG Committee of ASCO for Metastatic Breast Cancer, made the following post on X:
“Aleix Prat discusses promising Asian data especially from Fudan University Shanghai Cancer Centre with antibody drug conjugate SHR-A1811 demonstrating non-inferiority to the standard quadruple therapy in early Breast Cancer.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 2, 2025, 13:00
Apr 2, 2025, 12:35
Apr 2, 2025, 12:31
Apr 2, 2025, 12:29
Apr 2, 2025, 12:20